Evaluation of the Childhood Hodgkin International Prognostic Score (CHIPS) in High‐Risk Pediatric Hodgkin Lymphoma Patients Treated on Children's Oncology Group AHOD1331
Pediatric Blood & Cancer · 2025
DOI: 10.1002/pbc.31856 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Jennifer A Belsky und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Indiana University/Riley Hospital for Children, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Hodgkin Disease, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Quality Assurance Review Center, NCI NIH HHS, St. Baldrick's Foundation.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
CHIPS (Childhood Hodgkin International Prognostic Score), a predictive score for event‐free‐survival (EFS), was originally developed using factors presenting at diagnosis in patients with intermediate‐risk Hodgkin lymphoma (HL). Prospective validation of CHIPS in patients was a pre‐specified aim of AHOD1331, a trial comparing brentuximab‐vedotin, doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide (Bv‐AVEPC) to standard ABVE‐PC (and response‐adapted radiation) in children with high‐risk HL.
Methods
AHOD1331 was a multicenter randomized phase 3 study. Patients were aged 2–21 years with untreated stages IIB+bulk, IIIB, IV HL. CHIPS was determined by assigning one point each for: Stage IV disease, large mediastinal adenopathy (greater than one‐third thoracic diameter), albumin (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Indiana University/Riley Hospital for Children, Indianapolis, Indiana, USA.
- Division of Biostatistics, University of Southern California and Children's Oncology Group, Los Angeles, California, USA.
- Aflac Cancer and Blood Disorders Center, Emory University School of Medicine/Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
- Department of Radiation Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
- Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.
- Imaging and Radiation Oncology Core-Rhode Island, Lincoln, Rhode Island, USA.
ORCID-Profile: Jennifer A Belsky, Angela Punnett
Förderung
- Quality Assurance Review Center
- NCI NIH HHS
- St. Baldrick's Foundation
- NIH HHS
- National Institutes of Health
Zitieren
APA
Belsky, J. A., Renfro, L. A., Keller, F. G., Hodgson, D. C., Punnett, A., McCarten, K., Cho, S. Y., Wu, Y., Kelly, K. M., Castellino, S. M., & Schwartz, C. L. (2025). Evaluation of the Childhood Hodgkin International Prognostic Score (CHIPS) in High‐Risk Pediatric Hodgkin Lymphoma Patients Treated on Children's Oncology Group AHOD1331. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31856
Vancouver
Belsky JA, Renfro LA, Keller FG, Hodgson DC, Punnett A, McCarten K, et al. Evaluation of the Childhood Hodgkin International Prognostic Score (CHIPS) in High‐Risk Pediatric Hodgkin Lymphoma Patients Treated on Children's Oncology Group AHOD1331. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31856
BibTeX
@article{Belsky2025,
author = {Belsky, Jennifer A and Renfro, Lindsay A and Keller, Frank G and Hodgson, David C and Punnett, Angela and McCarten, Kathleen and Cho, Steve Y and Wu, Yue and Kelly, Kara M and Castellino, Sharon M and Schwartz, Cindy L},
title = {Evaluation of the Childhood Hodgkin International Prognostic Score (CHIPS) in High‐Risk Pediatric Hodgkin Lymphoma Patients Treated on Children's Oncology Group AHOD1331},
journal = {Pediatric Blood & Cancer},
year = {2025},
doi = {10.1002/pbc.31856}
}
EUVIMED